Phenylephrine pharmaceutical formulations and compositions for colonic absorption
View Patent ↗The invention discloses a pharmaceutical composition comprising phenylephrine or a pharmaceutically acceptable salt thereof and an erodible layer which is for oral administration wherein the composition delivers phenylephrine or a pharmaceutically acceptable salt thereof via absorption in the colon. The pharmaceutical composition comprises a core comprising phenylephrine or a pharmaceutically acceptable salt thereof and an erodible layer which is in a time-dependent, pH-dependent, or colon-specific enzyme-dependent erodible layer that degrades to expose the core to release phenylephrine in the colon. In one preferred embodiment, the erodible layer encases the core. The composition optionally further comprises phenylephrine in the erodible layer or other additional layer(s). The pharmaceutical composition can further comprise one or more additional therapeutically active agents selected from one or more of the group consisting of antihistamines, analgesics, anti-pyretics, and non-steroidal anti-inflammatory agents. The invention also discloses methods of administering phenylephrine via the colon, thereby increasing the bioavailable amount of therapeutically active unconjugated phenylephrine relative to the total phenylephrine in the plasma.
1. A pharmaceutical composition comprising phenylephrine and having two portions, wherein a first portion comprises phenylephrine in an immediate release form, which releases phenylephrine in a human's upper gastrointestinal system, and a second portion comprises phenylephrine in a sustained release form, which releases at least a portion of phenylephrine in a human's colon, wherein the composition contains 30 mg of phenylephrine and provides a mean C max and at least one of a mean AUC inf and the mean AUC 0-12 for phenylephrine under fasted conditions based on a single-dose administration that are from 80% to 125% of the mean C max and at least one of the mean AUC inf and the mean AUC 0-12 for phenylephrine provided by an extended release tablet containing 30 mg of phenylephrine and having an extended release core consisting essentially of about 22.5 mg of phenylephrine hydrochloride, about 25 mg of hydroxypropyl cellulose 300-600 cPs at 10%, about 25 mg of hydroxylpropyl cellulose 150-300 cPs at 2%, about 90 mg of carboxymethylcellulose sodium, about 332.5 mg of microcrystalline cellulose, and about 5 mg of magnesium stearate, and an immediate release coating layer consisting essentially of about 7.5 mg phenylephrine hydrochloride and about 36 mg polyvinylalcohol-based polymer.
2. The composition according to claim 1 , wherein phenylephrine is absorbed into the bloodstream such that the composition can be appropriately dosed once in a 12-hour period.
3. The composition according to claim 1 , wherein the composition completely dissolves within 4-12 hours of ingestion.
4. The composition according to claim 1 , wherein the phenylephrine dissolution profile of the composition comprises a zero-order release rate.
5. The composition according to claim 1 , wherein the mean C max and at least one of a mean AUC inf and the mean AUC 0-12 for phenylephrine provided by the composition are from about 80% to 125% of the mean C max and at least one of the mean AUC inf and the mean AUC 0-12 for phenylephrine provided by the extended release tablet at a 90% confidence interval.
6. The composition according to claim 1 , in which the extended release form comprises a polymer matrix.
7. The composition according to claim 1 or 6 , in which the immediate release form comprises a coating.
8. A pharmaceutical composition comprising phenylephrine and having two portions, wherein a first portion comprises phenylephrine in an immediate release form, which releases phenylephrine in a human's upper gastrointestinal system, and a second portion comprises phenylephrine in a sustained release form, which releases at least a portion of phenylephrine in a human's colon, wherein the composition contains 30 mg of phenylephrine and provides a mean C max and a mean AUC 0-4 for phenylephrine under fasted conditions based on a single-dose administration that are from 80% to 125% of the mean C max and the mean AUC 0-4 for phenylephrine provided by an extended release tablet containing 30 mg of phenylephrine and having an extended release core consisting essentially of about 22.5 mg of phenylephrine hydrochloride, about 25 mg of hydroxypropyl cellulose 300-600 cPs at 10%, about 25 mg of hydroxypropyl cellulose 150-300 cPs at 2%, about 90 mg of carboxymethyl cellulose sodium, about 332.5 mg of microcrystalline cellulose, and about 5 mg of magnesium stearate, and an immediate release coating layer consisting essentially of about 7.5 mg phenylephrine hydrochloride and about 36 mg polyvinylalcohol-based polymer, wherein t is a value of hours up to 24 hours.
9. The composition according to claim 8 , wherein the phenylephrine dissolution profile of the composition comprises a zero-order release rate.